Soleno Therapeutics (SLNO) Total Current Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Total Current Liabilities data on file, last reported at $58.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $58.0 million, up 269.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.0 million (up 269.01% YoY), and the FY2025 annual result was $61.4 million, up 227.32% from the prior year.
• Total Current Liabilities eased to $58.0 million in Q1 2026 per SLNO's latest filing, from $61.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $61.4 million in Q4 2025 and troughed at $7.2 million in Q2 2022.
• A 5-year average of $19.5 million and a median of $13.5 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 294.89% in 2023, then tumbled 48.39% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $7.3 million in 2022, then soared by 57.32% to $11.5 million in 2023, then surged by 62.95% to $18.7 million in 2024, then soared by 227.32% to $61.4 million in 2025, then decreased by 5.4% to $58.0 million in 2026.
• Business Quant data shows SLNO's Total Current Liabilities at $58.0 million in Q1 2026, $61.4 million in Q4 2025, and $33.3 million in Q3 2025.